

David A Foster

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7612595/publications.pdf>

Version: 2024-02-01

38
papers

2,375
citations

236925

25
h-index

315739

38
g-index

41
all docs

41
docs citations

41
times ranked

3587
citing authors

#	ARTICLE	IF	CITATIONS
1	Alcohol Consumption Raises HDL Cholesterol Levels by Increasing the Transport Rate of Apolipoproteins A-I and A-II. <i>Circulation</i> , 2000, 102, 2347-2352.	1.6	264
2	Phospholipase D in cell proliferation and cancer. <i>Molecular Cancer Research</i> , 2003, 1, 789-800.	3.4	233
3	The enigmatic protein kinase C δ : complex roles in cell proliferation and survival. <i>FASEB Journal</i> , 2004, 18, 627-636.	0.5	188
4	Phosphatidic acid signaling to mTOR: Signals for the survival of human cancer cells. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2009, 1791, 949-955.	2.4	182
5	Regulation of mTOR by Phosphatidic Acid?: Figure 1.. <i>Cancer Research</i> , 2007, 67, 1-4.	0.9	181
6	Targeting mTOR with rapamycin: One dose does not fit all. <i>Cell Cycle</i> , 2009, 8, 1026-1029.	2.6	119
7	Phospholipase D and the Maintenance of Phosphatidic Acid Levels for Regulation of Mammalian Target of Rapamycin (mTOR). <i>Journal of Biological Chemistry</i> , 2014, 289, 22583-22588.	3.4	108
8	Lipid sensing by mTOR complexes via de novo synthesis of phosphatidic acid. <i>Journal of Biological Chemistry</i> , 2017, 292, 6303-6311.	3.4	99
9	Phosphatidic acid and lipid-sensing by mTOR. <i>Trends in Endocrinology and Metabolism</i> , 2013, 24, 272-278.	7.1	89
10	Phospholipase D prevents apoptosis in v-Src-transformed rat fibroblasts and MDA-MB-231 breast cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2003, 302, 615-619.	2.1	85
11	The Enigma of Rapamycin Dosage. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 347-353.	4.1	80
12	Aspartate Rescues S-phase Arrest Caused by Suppression of Glutamine Utilization in KRas-driven Cancer Cells. <i>Journal of Biological Chemistry</i> , 2016, 291, 9322-9329.	3.4	59
13	Amino Acids and mTOR Mediate Distinct Metabolic Checkpoints in Mammalian G1 Cell Cycle. <i>PLoS ONE</i> , 2013, 8, e74157.	2.5	58
14	Rapamycin-induced G1 cell cycle arrest employs both TGF- β 2 and Rb pathways. <i>Cancer Letters</i> , 2015, 360, 134-140.	7.2	54
15	(-)-Oleocanthal rapidly and selectively induces cancer cell death via lysosomal membrane permeabilization. <i>Molecular and Cellular Oncology</i> , 2015, 2, e1006077.	0.7	53
16	Reciprocal Regulation of AMP-activated Protein Kinase and Phospholipase D. <i>Journal of Biological Chemistry</i> , 2015, 290, 6986-6993.	3.4	52
17	Glutamine as an Essential Amino Acid for KRas-Driven Cancer Cells. <i>Trends in Endocrinology and Metabolism</i> , 2019, 30, 357-368.	7.1	52
18	Synthetic lethality in KRas-driven cancer cells created by glutamine deprivation. <i>Oncoscience</i> , 2015, 2, 807-808.	2.2	43

#	ARTICLE	IF	CITATIONS
19	Phospholipase D-dependent mTOR complex 1 (mTORC1) activation by glutamine. <i>Journal of Biological Chemistry</i> , 2018, 293, 16390-16401.	3.4	41
20	5-Aminoimidazole-4-carboxamide-1- β -D-ribofuranoside (AICAR) enhances the efficacy of rapamycin in human cancer cells. <i>Cell Cycle</i> , 2015, 14, 3331-3339.	2.6	40
21	Targeting mTOR-mediated survival signals in anticancer therapeutic strategies. <i>Expert Review of Anticancer Therapy</i> , 2004, 4, 691-701.	2.4	31
22	Regulation of Phosphatidic Acid Phosphohydrolase by Epidermal Growth Factor. <i>Journal of Biological Chemistry</i> , 1996, 271, 29529-29532.	3.4	26
23	Myc stabilization in response to estrogen and phospholipase D in MCF-7 breast cancer cells. <i>FEBS Letters</i> , 2006, 580, 5647-5652.	2.8	26
24	Mutant Ras Elevates Dependence on Serum Lipids and Creates a Synthetic Lethality for Rapamycin. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 733-741.	4.1	26
25	Apoptotic effects of high-dose rapamycin occur in S-phase of the cell cycle. <i>Cell Cycle</i> , 2015, 14, 2285-2292.	2.6	26
26	Phospholipase D2 stimulates cell protrusion in v-Src-transformed cells. <i>Biochemical and Biophysical Research Communications</i> , 2002, 293, 201-206.	2.1	25
27	Phosphatidic acid drives mTORC1 lysosomal translocation in the absence of amino acids. <i>Journal of Biological Chemistry</i> , 2020, 295, 263-274.	3.4	19
28	A Late G1 Lipid Checkpoint That Is Dysregulated in Clear Cell Renal Carcinoma Cells. <i>Journal of Biological Chemistry</i> , 2017, 292, 936-944.	3.4	17
29	Inhibition of S6 kinase suppresses the apoptotic effect of eIF4E ablation by inducing TGF- β -dependent G1 cell cycle arrest. <i>Cancer Letters</i> , 2013, 333, 239-243.	7.2	16
30	(-)-Oleocanthal and (-)-oleocanthal-rich olive oils induce lysosomal membrane permeabilization in cancer cells. <i>PLoS ONE</i> , 2019, 14, e0216024.	2.5	16
31	Elevated phospholipase D activity in androgen-insensitive prostate cancer cells promotes both survival and metastatic phenotypes. <i>Cancer Letters</i> , 2018, 423, 28-35.	7.2	13
32	Elevated phospholipase D activity induces apoptosis in normal rat fibroblasts. <i>Biochemical and Biophysical Research Communications</i> , 2002, 298, 474-477.	2.1	12
33	Inhibition of fatty acid synthase induces pro-survival Akt and ERK signaling in K-Ras-driven cancer cells. <i>Cancer Letters</i> , 2014, 353, 258-263.	7.2	11
34	Reduced mortality and moderate alcohol consumption: The phospholipase D-mTOR connection. <i>Cell Cycle</i> , 2010, 9, 1291-1294.	2.6	9
35	Cancer cells with defective RB and CDKN2A are resistant to the apoptotic effects of rapamycin. <i>Cancer Letters</i> , 2021, 522, 164-170.	7.2	7
36	Metabolic vulnerability of KRAS-driven cancer cells. <i>Molecular and Cellular Oncology</i> , 2014, 1, e963445.	0.7	5

#	ARTICLE	IF	CITATIONS
37	Albumin promotes the progression of fibroblasts through late G ₁ into S-phase in the absence of growth factors. <i>Cell Cycle</i> , 2020, 19, 2158-2167.	2.6	3
38	Hidesaburo Hanafusa (1929–2009). <i>Nature</i> , 2009, 458, 718-718.	27.8	0